Christopher Lang, MD
Cardiovascular Disease · Bangor, MENPI 1972745917
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $2,257 of the $3,281 with a category attached, or 68.8%. 5 manufacturers reported payments, led by Abbott at 51.3% of the total. Reporting peaked in 2019 at $1,715 and has fallen 91.3% since, to $148 in 2025.
Across 26 payments — averaging $126.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$2K
- Ancora Heart, Inc.$1K
- Edwards Lifesciences$99
- Stryker$65
- GE HealthCare$16
Across 25 payments — averaging $12,355 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$234K
- Amgen$75K
What the payments were for
- Travel & lodging$2,25769%
- Food & beverage$1,02431%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 16 | $1,684 |
| Ancora Heart, Inc. | 6 | $1,417 |
| Edwards Lifesciences | 2 | $99 |
| Stryker | 1 | $65 |
| GE HealthCare | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Mitra Clip system$1,313
- AccuCinch$1,273
How this compares
$3,281 in reported general payments places this provider in the 85th percentile of 99 cardiovascular disease providers in Maine.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 11 | $17,959 |
| JardianceEmpagliflozin | 14 | $17,355 |
| FarxigaDapagliflozin Propanediol | 12 | $16,644 |
| Praluent PenAlirocumab | 12 | $9,736 |
| Dofetilide | 18 | $6,033 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 12 | $1,929 |
| Amiodarone Hcl | 33 | $462 |
| Bumetanide | 15 | $432 |
| SotalolSotalol Hcl | 20 | $344 |
| Metoprolol Succinate | 16 | $196 |
| Atorvastatin Calcium | 11 | $73 |
| Furosemide | 17 | $50 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Bangor
- Sverrir GunnarssonBangor$2K
- Eddy KarnabiBangor$2K
- Chae ChoiBangor$2K
- Rupert FinckeBangor$2K
- Thorarinn BjarnasonBangor$741
- Alan WisemanBangor$583
- Qurat Ul Ain JelaniBangor$429
- Christine RutlenBangor$364
- Peter Ver LeeBangor$327
- Jims Jean-JacquesBangor$285
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.